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Tumor necrosis factor a (TNFa) (also called cachectin) exhibits a wide range of
biological activities (1). When injected into animals, TNF-a may induce circulatory
failure and death, and the lethality induced by LPS or Gram-negative bacteria may
be inhibited by antibodies to TNF-a (2-4). The protein thus appears to play a role
in the pathogenesis of septic shock (5). The multiple biological activities of TNF-a
are overlapping with those of IL-1 (6). Both cytokines may increase the adherence
of neutrophils, induce fever in the rabbit, and induce a procoagulant activity in en-
dothelial cells (7-9). However, the role ofIL-1 in septic shock remains to be clarified.
We have previously reported that the presence of TNF-a in serum is associated
with fatal outcome in patients with meningococcal disease (10). Recently, we have
detected IL-1 activity in serum from three patients with septic shock (Waage, A.,
P. Brandtzaeg, A. Halstensen, and T. Espevik, manuscript in preparation). These
patients had high serum levels of TNF-a and rapid fatal outcomes. This observation
led us to the hypothesis that TNFa and IL-1 may have synergistic lethal effect in
septic shock. The present study gives support to this hypothesis by demonstrating
that recombinant IL-la (rIL-1a) and IL-1(3 (rIL-1(3) markedly potentiate the lethal
effect of recombinant TNF-a (rTNF-a) in mice.
Materials and Methods
BriefDefinitive Report
Reagents.
￿
Mouse rTNF-a (Dr. G. R. Adolf, BoehringerIngelheim, Vienna, Austria) had
a specific activity of 7 x 107 U/mg as determined by a cytotoxicity assay using L-M cells,
and contained <0.025 ng of endotoxin/mg of recombinant protein by the limulus amoebo-
cyte lysate test (11, 12). Human rIL-la (Glaxo Institute for Molecular Biology, Geneva, Swit-
zerland) had a specific activity of 2 .5 x 10' U/mg as determined in the thymocyte prolifera-
tion assay (13), and human rIL-1R (Glaxo) had a specific activity of 5 x 101 U/mg (14). The
contents of endotoxin were specified to be 0.4-0.7 ng/mg of rIL-la and 0.007-0.014 ng/mg
of rIL-1(3 (limulus amoebocyte lysate test)(13, 14). The cytokines were diluted in endotoxin-
free 0.9% saline to appropriate concentrations, and injected in a volume of 0.1 ml into each
mouse via the tail vein. An antiserum against rIL-la has been raised in sheep, and neutral-
ized at least 20 wg rIL-1a/ml antiserum (a gift from Dr. A. Shaw, Glaxo). Control serum
was taken from a normal sheep. LPS from Escherichia coli (026:B6) was purchased from Sigma
Chemical Co., St. Louis, MO.
Animals.
￿
Male NMRI mice (Bomholt Bard, Ry, Denmark) weighing 22-24 g were caged
in groups at room temperature 22°C, and were allowed to eat and drink ad libitum.
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FIGURE 1 .
￿
Lethality in groups ofmice receivingvar-
ious combinations of mouse rTNF-a and human
rIL-la and human rIL-1(i . The numbers along the
abscissa denote the dose of rTNF-a per mouse, and,
when not specified in the figure, the dose of rIL-1 .
The number of mice in each group was 8-15, and
the observation period was 72 h .
Results
Mice receiving doses of rIL-la or rIL-1ß from 0.15 to 1.8 jig/mouse were active
and appeared to be healthy during the observation period . No deaths were recorded
in these groups of animals (Fig . 1) .
A dose-response curve for rTNFa with respect to lethality was determined (Fig .
1) . The lowest dose ofrTNFa causing death was 0.5 jig/mouse, and the dose ofrTNFa
causing 50% death (LD5o) was 1.5 jig/mouse, as estimated by the regression line
on the curve in Fig . 1 . 98% of all the deaths occurred within 12 h of injection .
Concomitant with the administration of rTNFa to one group of mice, animals
in a parallel group received the same dose ofrTNFa combined with 0.5 wg rIL-l a .
The combination of the two cytokines was far more toxic than any of them given
alone, and the LD5o of rTNFa in this combination was calculated to be 0.4
jig/mouse (Fig . 1) . A similar effect of rIL-1ß (0.5 jig/mouse) and rTNFa was ob-
served, as the LD5o of rTNFa administered in this combination was calculated to
be 0.5 jig/mouse. The analysis of these results showed that the effects ofthe cytokines
were not merely additive, but that rIL-la and rIL-lß potentiated the lethal effect
of TNFa (15) .
FIGURE 2 . Survival curves after injection of
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TABLE I
Protection by Antiserum to rIL-la
Number of
Treatment*
￿
dead mice
rTNF-a/rIL-la and rIL-la antiserum
￿
1/5
rTNF-a/rIL-la and control serum
￿
4/5
rTNF-a and control serum
￿
1/5
* 0 .6 gg of rTNF-a, 0 .4 Vg of rIL-la and 90 g1 HL-la antiserum or control se-
rum was injected in a volume of 100 w1 into each animal . The mice were ob-
served for 24 h .
1989
Fig. 2 shows survival curves that clearly demonstrate the potentiating effect of
rIL-1a . The combination of a near nonlethal dose of rTNFa and a nonlethal dose
of rIL-la induced 100% lethality within 10 h of injection of the cytokines . In com-
parison, 1 gg of rTNFa induced 30% lethality.
To evaluate the specificity of the potentiating effect of rIL-1 a, mixtures ofrTNF
a, rIL-la, and antiserum to rIL-la or control serum were incubated at 37°C for
1 h before injection. In the group ofmice receivingamixture containing antiserum,
1 of 5 mice died, whereas 4 of 5 mice died in the group receiving control serum
(Table I) . Also, LPS has been reported to potentiate the lethal effect of TNFa in
mice (16), and control experiments were conducted to assess the possible influence
ofLPS contamination . Solutions containing 0.5 jig ofrTNFa and various amounts
ofLPS were injected into mice, and enhanced lethality was observed when the LPS
doses were >1 wg/mouse (data not shown) . Injections ofLPS alone, orLPS together
with 0.5 wg of rIL-1a, did not cause death for LPS doses up to 200 ug/mouse . Al-
together, these results indicate that the rTNFa potentiating effect of the rIL-1 prepa-
rations were caused by the IL-1 molecule itself and not by the LPS content in the
preparations of cytokines .
In mice, a dual effect ofrTNFa on the temperature has been reported, as low
doses may induce fever and high doses produce a marked hypothermia (17) . In all
our experiments, rTNFa had a hypothermic effect, and results from one experi-
ment are shown in Fig . 3 . The lowest mean temperature recorded after injection
of 0.375 ItgofrTNFa was 33.4°C . When rTNFa was combined with 0.5 gg/mouse
FIGURE 3 .
￿
Temperatures in mice receiving various
combinations of cytokines . The doses given were
0.375 ug/mouse of rTNF-a and 0 .5 wg/mouse of rIL:
1 . Results are mean + SEM .1990
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of rIL-la or rIL-1 a, the lowest mean temperatures detected were 28.4°C and 31.6°C,
respectively. A similar pattern in the temperature responses was observed in all ex-
periments.
Discussion
The results demonstrate that the LD5o or rTNF-a was reduced by -70% when
rTNF-a was administered together with a nonlethal dose of rIL-la or rIL-1a . A similar
effect was observed on the temperature response, and we conclude that the rIL-1
markedly potentiate the lethal and hypothermic effects of rTNF-a. By comparing
rIL-la and rIL-1(3 on a weight basis, rIL-1a seemed to have a slightly stronger poten-
tiating effect than rIL-1(3 .
It has been reported that also LPS may potentiate the lethal effect of TNF-a in
mice (16), and it appears to be important to evaluate the possibility of LPS contami-
nation in our experiments. We found that it was required to inject >1 Pg/mouse
of LPS in order to potentiate the lethal effect or rTNF-a. Rothstein and Schreiber
have reported a similar potentiating effect with LPS doses at 24 ng/mouse, or higher
(16). In comparison, the maximum dose of LPS injected in a mixture of 0 .5 gg of
rTNF-a and 0 .5 wg of rIL-1a was 0.4 pg. This dose is _106 times lower than the crit-
ical LPS dose determined in our control experiments, and could hardly be the cause
of the potentiating effect of the rIL-1 preparations.
Furthermore, we demonstrated that neutralization of rIL-la resulted in a protec-
tion from the lethal effect of the combination of rTNFa and rIL-l a . Altogether, the
control experiments strongly indicate that the potentiating effect observed in the
present study can be assigned to IL-1 .
Ruggiero and Baglioni (18) have previously reported a synergistic antiprolifera-
tive effect of TNF-a and IL-1 on a human melanoma cell line. In contrast, additive
effects of TNFa and IL-1 have been observed with respect to the suppression of
a lipoprotein lipase in 3T3-Ll cells, and the induction of procoagulant activity in
endothelial cells (9, 19). At the cellular level, it thus appears that the effects of IL-1
and TNF-a may be either additive or synergistic. Despite many similarities in the
biological activities, TNF-a and IL-1 appears to bind to different receptors (19, 20).
What happens beyond the receptor level after binding of their respective cytokines,
and the basis of the observed synergistic effects, is incompletely understood . The
in vivo responses observed in the present study are probably mediated via complex
biochemical and cellular reactions, and even more difficult to explain .
During the initial phase of septic shock, a number of cytokines are probably released
into the circulation . The identification of these cytokines and their actions and in-
teractions in septic shock appears to be important in order to direct new strategies
for the treatment of these patients. We have observed that patients with high levels
of TNF-a and detectable amount of IL-1 in the circulation rapidly died from septic
shock. The results in the present study support our suggestion that IL-1 and TNF-a
may have synergistic lethal effect in human septic shock.
Summary
Human rIL-la and human rIL-1R were examined for their ability to potentiate
the lethal and hypothermic effects of mouse rTNF-a in mice. The LD5o of rTNF-a
was 1.5 gg/mouse, whereas the LD5o of rTNF-a was reduced to 0.4 ug/mouse andWAAGE AND ESPEVIK BRIEF DEFINITIVE REPORT
￿
199 1
0.5 wg/mouse when rTNFa was administered in combination with a nonlethal dose
of rIL-la or rIL-la, respectively. A similar rTNFa enhancing effect of the rIL-1 was
observed on the temperature response. The results show that the rIL-1 markedly
potentiate the effects of rTNFa on lethality and temperature in mice, and support
our suggestion that TNFa and IL-1 may have synergistic lethal effect in human
septic shock.
Receivedfor publication 11 March 1988.
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